{
    "nctId": "NCT01669252",
    "briefTitle": "Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer",
    "officialTitle": "A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALAVEN\u00ae) as Neoadjuvant Treatment for Operable Stage I-II HER2 Non-overexpressing Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 163,
    "primaryOutcomeMeasure": "Correlation of pre-treatment relative abundance of hundreds of mRNA transcripts from primary breast tumors with pCRB after neoadjuvant treatment with eribulin.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent, specifically highlighting the molecular characterization of tumor and genomic samples\n* Age \u226518 years\n* Histologically confirmed invasive breast carcinoma, with all of the following characteristics:\n\n  * Primary tumor \u22652cm in largest diameter (cT1-3)\n  * cN0-1\n  * No evidence of distant metastasis (M0)\n* Breast cancer (BC) eligible for primary surgery\n* Available pre-treatment core (Tru-cut) biopsy or possibility of performing one\n* HER2-negative BC (as per local assessment), defined as either of the following:\n\n  * 0-1+ expression by IHC\n  * 2+ expression by IHC and in situ hybridization (FISH/CISH) without HER2 gene amplification (\\<4 HER2 gene copies per nucleus, or a FISH ratio \\[HER2 gene copies to Cr17 signals\\] of \\<1.8)\n  * Is situ hybridization (FISH/CISH) without HER2 gene amplification, independently of IHC\n* Known hormone receptor (ER/PgR) status (as per local assessment) or the possibility of performing the tests\n* Known percentage of hormone receptor (ER/PgR) and Ki67-positive tumor cells (as per local assessment), or possibility of performing the tests\n* In the case of a multifocal tumor, the largest lesion must be \u22652 cm and designated the \"target\" lesion for all subsequent tumor evaluations and HER2-negative status must be documented in all the tumor foci\n* ECOG performance status of 0 or 1\n* Laboratory values as follows:\n\n  * Absolute neutrophil count (ANC) \u22651.5 x 109/L\n  * Platelets count \u2265100 x 109/L\n  * Hemoglobin \u22659 g/dL\n  * Serum bilirubin \u22641.5 time the upper limit of normal (ULN)\n  * Alanine aminotransferase and aspartate aminotransferase (AST) \u22642.5 x ULN\n  * Alkaline phosphatase \u22642.5 x ULN\n  * Serum creatinine \u22641.5 mg/dL or calculated creatinine clearance \u226560 mL/m\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol\n* Availability of genomic DNA (via whole blood)\n\nExclusion Criteria:\n\n* Any prior treatment for primary invasive BC\n* Metastatic, locally advanced or inflammatory (i.e., Stage III-IV) BC\n* Bilateral invasive BC\n* Multicentric BC, defined as the presence of two or more foci of cancer in different quadrants of the same breast\n* Pre-existing peripheral neuropathy of any grade\n* Uncontrolled hypertension (systolic \\>150 mmHg and/or diastolic \\>100 mmHg)\n* Clinically significant (i.e., active) cardiovascular disease\n* Long QT syndrome\n* Concomitant use of inhibitors of hepatic transport proteins such as organic anion-transporting proteins, P-glycoprotein, multidrug resistant proteins etc\n* Major medical conditions that might affect study participation (e.g., uncontrolled seizure disorder, uncontrolled pulmonary, renal or hepatic dysfunction, or uncontrolled infection)\n* Other primary malignant tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix\n* Known human immunodeficiency virus(HIV) infection or other active or serious infection requiring IV antibiotics at randomization\n* Pregnancy or breastfeeding women\n* Women of childbearing potential(\\<2 years after the last menstruation) not using effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug\n* Administration of any live virus vaccine within 8 weeks preceding study entry\n* Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study\n* Requirement for radiation therapy concurrent with study anticancer treatment\n* Known hypersensitivity to any of the study drugs or excipients\n* Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}